Pay in 4 interest-free payments of $7.48 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Ozempic, Wegovy, Mounjaro, and Zepbound and their delivery device are registered trademarks
Food and Drug Administration: (May 2022) Approved as adjunct to diet and exercise for glycemic control in adults with type 2 diabetes mellitus (November 2023) Approved for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity (December 2024) Expanded indication for moderate-to-severe obstructive sleep apnea in adults with obesity Classified as first-in-class dual GIP/GLP-1 receptor agonist Not approved for type 1 diabetes mellitus or as monotherapy in patients with history of pancreatitis International Regulatory Approvals GLP2 has received regulatory approval in multiple jurisdictions: European Union (September 2022) Type 2 diabetes treatment United Kingdom (November 2023) Expanded to include weight management Canada (November 2022) Type 2 diabetes indication Australia (December 2022) Type 2 diabetes treatment Additional regulatory reviews ongoing in other countries Warnings and Contraindications Important safety considerations include: Boxed Warning for thyroid C-cell tumor risk (based on rodent studies
6, 2021), [31] Alyson Powell Key & Marijke Vroomen Durning, Ileus: What Is It
It's a platform
